Pacira BioSciencesPCRX
PCRX
About: Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Employees: 712
0
Funds holding %
of 6,790 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
26% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 68
17% more call options, than puts
Call options by funds: $6.72M | Put options by funds: $5.74M
2.07% less ownership
Funds ownership: 112.65% [Q2] → 110.58% (-2.07%) [Q3]
15% less funds holding
Funds holding: 277 [Q2] → 236 (-41) [Q3]
46% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 90
49% less capital invested
Capital invested by funds: $1.5B [Q2] → $768M (-$732M) [Q3]
75% less funds holding in top 10
Funds holding in top 10: 4 [Q2] → 1 (-3) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
22%
downside
Avg. target
$21
10%
upside
High target
$39
103%
upside
6 analyst ratings
3 positive
50%
3 neutral
50%
0 negative
0%
HC Wainwright & Co. Oren Livnat 44% 1-year accuracy 16 / 36 met price target | 103%upside $39 | Buy Reiterated | 4 Dec 2024 |
Barclays Balaji Prasad 47% 1-year accuracy 16 / 34 met price target | 12%downside $17 | Equal-Weight Maintained | 12 Nov 2024 |
Needham Serge Belanger 47% 1-year accuracy 55 / 118 met price target | 14%upside $22 | Buy Reiterated | 8 Nov 2024 |
RBC Capital Gregory Renza 48% 1-year accuracy 31 / 65 met price target | 17%downside $16 | Sector Perform Maintained | 7 Nov 2024 |
RBC Capital Gregory Renza 48% 1-year accuracy 31 / 65 met price target | 22%downside $15 | Sector Perform Maintained | 4 Oct 2024 |
Financial journalist opinion
Based on 16 articles about PCRX published over the past 30 days
Neutral
Accesswire
5 hours ago
PCRX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Pacira BioSciences, Inc. Investment
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Neutral
Zacks Investment Research
1 day ago
PCRX Receives New Patent for Lead Pain Drug Exparel in the US
The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.
Neutral
Accesswire
1 day ago
PCRX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Pacira BioSciences, Inc.
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Neutral
GlobeNewsWire
2 days ago
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 --
Neutral
Accesswire
2 days ago
An Investigation Has Commenced on Behalf of Pacira BioSciences, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PCRX Losses.
NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Positive
Zacks Investment Research
6 days ago
Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Neutral
Accesswire
6 days ago
Pacira BioSciences, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PCRX
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Neutral
Accesswire
1 week ago
ATTENTION Pacira BioSciences, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Negative
Seeking Alpha
1 week ago
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's share price has plummeted from >$80 in mid-2022 to ~$18 today, as the market sees little growth in the business and notes the competitive threats.
Neutral
Accesswire
1 week ago
Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerning possible violations of federal securities laws. On August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement.
Charts implemented using Lightweight Charts™